Genprex, Inc.
GNPXHealthcare|Biotechnology|US
$2.07
-0.03 (-1.43%)
DCF Value
$168.10
Tangible Book / Share
$31.27
Cash / Share
$32.03
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05703971 Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | Small Cell Lung Cancer Extensive Stage | P1P2 | Recruiting | 62 | Open-label | quaratusugene ozeplasmid, atezolizumab |
| NCT04486833 Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | Carcinoma, Non-Small Cell Lung | P1P2 | Recruiting | 158 | RCT, Open-label | quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy |
| NCT01455389 TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer | Lung Cancer | P1P2 | Terminated | 25 | Open-label | DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone, Diphenhydramine |
| NCT05062980 Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer | Non Small Cell Lung Cancer | P1 | Terminated | 5 | RCT, Open-label | quaratusugene ozeplasmid, pembrolizumab, docetaxel, ramucirumab, Investigator's Treatment of Choice |